Clinical Trial Update: Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of interferon alfa-2b (Intron A) for metastatic or unresectable clear cell renal cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Intron A (interferon alfa-2b)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Renal Cancer | Phase 2 | Status: WITHDRAWN